Big Pharma Embraces Pharmacogenomics - But Are We There Yet? : Market Research Report

Big Pharma Embraces Pharmacogenomics - But Are We There Yet?

Published: Aug. 22, 2006 - 31 Pages

Price reduced due to age.

Contents: Executive Summary
Strategic Considerations: Stakeholder Implications
Pharmacogenomics in Practice: Leaders in the Implementation of PGx
Celera Genomics: Illumina
Perlegen Sciences: Well-Documented Patient Data Are Paramount
DeCode Genetics-Icelandic Population: Spectrum Expert Commentary: Difficulties in Using Founder Populations
The Mayo Clinic-Olmsted County Epidemiology Data: Genizon-Quebec French Canadian Founder Population
Industry's Current Use of Pharmacogenomics: Preclinical Drug Development
DeCode Genetics-Identifying New Drug Targets: Improving Safety and Efficacy of New Drugs
Patient Segmentation: Genentech/Roche/Chugai's Trastuzumab (Herceptin)
Clinical Data/Genaissance's Vilazodone: Perlegen's MCC-555
Encode's Information-Rich Clinical Trials: Drug Dosing and Metabolism
NeoPharm's LE-SN38: Warfarin (Bristol-Myers Squibb's Coumadin)
Azathioprine and Mercaptopurines: Adverse Drug Reactions; GlaxoSmithKline's Abacavir (Ziagen)
Eli Lilly's Atomoxetine (Strattera): Post-Marketing Efficacy Issues
Epidermal Growth Factor Receptor-Based Drugs: Clinical Data and Genaissance's STRENGTH and CARING Studies
Major Challenges: Regulatory Issues
Reimbursement, Ethical, and Legal Issues: Spectrum Expert Commentary: FDA Establishes New Processes:
Pharmacogenomic Data Submissions and a Drug-Test Codevelopment Pathway: Outlook
Tables: 1. Financial Position of Key PGx Leaders, FY05; 2. Select Celera Collaborations; 3. Disease Correlations Identified by Celera; 4. Select Perlegen Collaborations; 5. Populations for Disease Correlation and PGx Studies; 6. Effect of Genotype on Drug-Drug Interactions
A. Examples of Different Categories of Biomarkers: 7. Select PGx Diagnostics
Figures: 1. Potential of PGx in Practice; 2. Founder Populations; 3. Genomewide Scans and SNP Mapping; 4. Genome-Based Drug Doses for Antidepressants; 5. UGT1A1 Genotype Testing Before Irinotecan Rx
A. Drug-Test Codevelopment Process

Abstract

Pharmacogenomics will revolutionize the drug industry by linking the right drug to the right patient. Several companies and regulatory agencies are leading the charge to implement this approach of developing targeted medicines. PGx's integration is inevitable; pharma companies must get on board now or risk being left behind.

Get the Answers You Need to Shape Your Strategy
Big pharma companies have become increasingly interested in PGx. These companies realize that PGx offers a way to develop better and safer drugs.

Which companies are leading the charge to integrate PGx into drug discovery and development?
Appropriate genetic markers and well-documented patient samples are critical to determining disease correlations.

How are companies obtaining this information, and how are they using it to create personalized medicines?

Although PGx is being integrated into many aspects of drug discovery and development, many regulatory and ethical challenges persist.

What are the major issues remaining, and what are companies and regulatory agencies doing to overcome these challenges?

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Big Pharma Embraces Pharmacogenomics - But Are We There Yet?

Table of Contents

Abstract